M&A Year in Review 2023 brochure - Flipbook - Page 34
34
Life Sciences
and Health Care
Sector performance
M&A activity in the life sciences and health care
industry remained resilient in 2023, despite continued
regulatory,
geopolitical,
and
macroeconomic
headwinds. While the overall volume of deals in the
sector fell year on year, overall value increased as
a result of megadeals in the pharmaceutical and
medtech space.
In the race toward innovation, the industry continued
to focus on digitalization through increased investment
in digital health, AI, and tech-enabled offerings. The
industry also continued a long-standing trend of using
milestones and earnouts to bridge valuation gaps.
Hogan Lovells activities
Our Life Sciences and Health Care team hosted events
and produced podcasts to help clients stay ahead of
industry trends.
We released our annual Life Sciences and Health
Care Horizons publication, providing an analysis
of key considerations for companion diagnostic
collaborations, among other forward-looking transaction
topics. We continued to share high-level insights into
opportunities and challenges in the sector through our
Talking the Cure podcast series.
